Karas Eric 4
4 · ARS Pharmaceuticals, Inc. · Filed Jul 3, 2025
Insider Transaction Report
Form 4
Karas Eric
Chief Commercial Officer
Transactions
- Sale
Common Stock
2025-07-01$16.99/sh−15,000$254,861→ 10,315 total - Exercise/Conversion
Common Stock
2025-07-01$1.50/sh+15,000$22,500→ 25,315 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-07-01−15,000→ 544,588 totalExercise: $1.50Exp: 2032-05-23→ Common Stock (15,000 underlying)
Footnotes (4)
- [F1]Includes 2,619 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025.
- [F2]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
- [F3]The weighted average sale price for the transaction reported was $16.9907, and the range of prices were between $16.71 and $17.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]Immediately exercisable.